The U.S. Food and Drug Administration (FDA) is responsible for ensuring the safety, efficacy, and security of drugs, biological products, and medical devices. FDA experts review the results of laboratory, animal, and human clinical testing done by manufacturers of these products. If FDA grants an approval, it means the agency has determined that the benefits of the product outweigh the known risks for the intended use and the product can be marketed in the United States.
The following anticancer therapeutics have recently received FDA approval.
Targeting Several Blood Cancers
September 24, 2018: The FDA has approved a new molecularly targeted therapeutic called duvelisib for treating certain patients with is intended for patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma.
Combining Immunotherapy for Kidney Cancer
April 16, 2018: The FDA has approved a combination of the immunotherapeutics ipilimumab and nivolumab for treating intermediate- or poor-risk advanced renal cell carcinoma that was previously untreated.
Top of page